Novel patterns of response under immunotherapy

E. Borcoman, Y. Kanjanapan, S. Champiat, S. Kato, V. Servois, R. Kurzrock, Sanjay Goel, P. Bedard, C. Le Tourneau

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough with immunotherapy is its potential to achieve durable responses in a subset of patients with advanced cancer that can be maintained several years even after stopping the treatment. No standardized definition of durable response exists in the literature, and the optimal duration of treatment in case of durable response is not clearly established. However, the majority of patients do not respond to immunotherapy. Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression. Overall, reported rates of pseudoprogression never exceeded 10%, meaning that the large majority of patients who have a disease progression will not eventually respond to treatment. The decision to pursue treatment beyond progression must therefore only be taken in carefully selected patients with clinical benefit, who did not experience severe toxicities with immunotherapy. Conversely, rapid progressions, called hyperprogressions, were reported by several teams with rates ranging from 4% to 29%. These observations need to be confirmed from randomized trials. It is essential to interrupt the treatment in patients with hyperprogression, in order to switch to another potentially active treatment. Finally, some patients experience dissociated responses, with some lesions shrinking and others growing. Local treatment with surgery or radiotherapy for growing lesions may be considered. Several immune-specific-related response criteria were developed to better capture benefits of immunotherapy. These criteria only address the pseudoprogression pattern of response, and do not capture the other patterns of response such as hyperprogression and dissociated response. The classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.

Original languageEnglish (US)
Pages (from-to)385-396
Number of pages12
JournalAnnals of Oncology
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Immunotherapy
Therapeutics
Disease Progression
Melanoma
Neoplasms
Radiotherapy

Keywords

  • durable response
  • hyperprogression
  • immunotherapy
  • pseudoprogression
  • response assessment
  • treatment beyond progression

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Borcoman, E., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., ... Le Tourneau, C. (2019). Novel patterns of response under immunotherapy. Annals of Oncology, 30(3), 385-396. https://doi.org/10.1093/annonc/mdz003

Novel patterns of response under immunotherapy. / Borcoman, E.; Kanjanapan, Y.; Champiat, S.; Kato, S.; Servois, V.; Kurzrock, R.; Goel, Sanjay; Bedard, P.; Le Tourneau, C.

In: Annals of Oncology, Vol. 30, No. 3, 01.03.2019, p. 385-396.

Research output: Contribution to journalReview article

Borcoman, E, Kanjanapan, Y, Champiat, S, Kato, S, Servois, V, Kurzrock, R, Goel, S, Bedard, P & Le Tourneau, C 2019, 'Novel patterns of response under immunotherapy', Annals of Oncology, vol. 30, no. 3, pp. 385-396. https://doi.org/10.1093/annonc/mdz003
Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R et al. Novel patterns of response under immunotherapy. Annals of Oncology. 2019 Mar 1;30(3):385-396. https://doi.org/10.1093/annonc/mdz003
Borcoman, E. ; Kanjanapan, Y. ; Champiat, S. ; Kato, S. ; Servois, V. ; Kurzrock, R. ; Goel, Sanjay ; Bedard, P. ; Le Tourneau, C. / Novel patterns of response under immunotherapy. In: Annals of Oncology. 2019 ; Vol. 30, No. 3. pp. 385-396.
@article{87258bc196a846b89e5a35eaeff24656,
title = "Novel patterns of response under immunotherapy",
abstract = "Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough with immunotherapy is its potential to achieve durable responses in a subset of patients with advanced cancer that can be maintained several years even after stopping the treatment. No standardized definition of durable response exists in the literature, and the optimal duration of treatment in case of durable response is not clearly established. However, the majority of patients do not respond to immunotherapy. Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression. Overall, reported rates of pseudoprogression never exceeded 10{\%}, meaning that the large majority of patients who have a disease progression will not eventually respond to treatment. The decision to pursue treatment beyond progression must therefore only be taken in carefully selected patients with clinical benefit, who did not experience severe toxicities with immunotherapy. Conversely, rapid progressions, called hyperprogressions, were reported by several teams with rates ranging from 4{\%} to 29{\%}. These observations need to be confirmed from randomized trials. It is essential to interrupt the treatment in patients with hyperprogression, in order to switch to another potentially active treatment. Finally, some patients experience dissociated responses, with some lesions shrinking and others growing. Local treatment with surgery or radiotherapy for growing lesions may be considered. Several immune-specific-related response criteria were developed to better capture benefits of immunotherapy. These criteria only address the pseudoprogression pattern of response, and do not capture the other patterns of response such as hyperprogression and dissociated response. The classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.",
keywords = "durable response, hyperprogression, immunotherapy, pseudoprogression, response assessment, treatment beyond progression",
author = "E. Borcoman and Y. Kanjanapan and S. Champiat and S. Kato and V. Servois and R. Kurzrock and Sanjay Goel and P. Bedard and {Le Tourneau}, C.",
year = "2019",
month = "3",
day = "1",
doi = "10.1093/annonc/mdz003",
language = "English (US)",
volume = "30",
pages = "385--396",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Novel patterns of response under immunotherapy

AU - Borcoman, E.

AU - Kanjanapan, Y.

AU - Champiat, S.

AU - Kato, S.

AU - Servois, V.

AU - Kurzrock, R.

AU - Goel, Sanjay

AU - Bedard, P.

AU - Le Tourneau, C.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough with immunotherapy is its potential to achieve durable responses in a subset of patients with advanced cancer that can be maintained several years even after stopping the treatment. No standardized definition of durable response exists in the literature, and the optimal duration of treatment in case of durable response is not clearly established. However, the majority of patients do not respond to immunotherapy. Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression. Overall, reported rates of pseudoprogression never exceeded 10%, meaning that the large majority of patients who have a disease progression will not eventually respond to treatment. The decision to pursue treatment beyond progression must therefore only be taken in carefully selected patients with clinical benefit, who did not experience severe toxicities with immunotherapy. Conversely, rapid progressions, called hyperprogressions, were reported by several teams with rates ranging from 4% to 29%. These observations need to be confirmed from randomized trials. It is essential to interrupt the treatment in patients with hyperprogression, in order to switch to another potentially active treatment. Finally, some patients experience dissociated responses, with some lesions shrinking and others growing. Local treatment with surgery or radiotherapy for growing lesions may be considered. Several immune-specific-related response criteria were developed to better capture benefits of immunotherapy. These criteria only address the pseudoprogression pattern of response, and do not capture the other patterns of response such as hyperprogression and dissociated response. The classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.

AB - Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough with immunotherapy is its potential to achieve durable responses in a subset of patients with advanced cancer that can be maintained several years even after stopping the treatment. No standardized definition of durable response exists in the literature, and the optimal duration of treatment in case of durable response is not clearly established. However, the majority of patients do not respond to immunotherapy. Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression. Overall, reported rates of pseudoprogression never exceeded 10%, meaning that the large majority of patients who have a disease progression will not eventually respond to treatment. The decision to pursue treatment beyond progression must therefore only be taken in carefully selected patients with clinical benefit, who did not experience severe toxicities with immunotherapy. Conversely, rapid progressions, called hyperprogressions, were reported by several teams with rates ranging from 4% to 29%. These observations need to be confirmed from randomized trials. It is essential to interrupt the treatment in patients with hyperprogression, in order to switch to another potentially active treatment. Finally, some patients experience dissociated responses, with some lesions shrinking and others growing. Local treatment with surgery or radiotherapy for growing lesions may be considered. Several immune-specific-related response criteria were developed to better capture benefits of immunotherapy. These criteria only address the pseudoprogression pattern of response, and do not capture the other patterns of response such as hyperprogression and dissociated response. The classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.

KW - durable response

KW - hyperprogression

KW - immunotherapy

KW - pseudoprogression

KW - response assessment

KW - treatment beyond progression

UR - http://www.scopus.com/inward/record.url?scp=85064114046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064114046&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz003

DO - 10.1093/annonc/mdz003

M3 - Review article

C2 - 30657859

AN - SCOPUS:85064114046

VL - 30

SP - 385

EP - 396

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -